BCAL DiagnosticsASX:BDX -1.39% EPS without NRI is A$-0.02 as of Dec. 2025. The stock has 3 warning signs investors should review. Among 160 Medical Diagnostics & Research companies, BCAL Diagnostics ranks worse than 73.13% on this metric.
BCAL Diagnostics's earnings per share without non-recurring items for the
six
months ended in Dec. 2025 was A$-0.01.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.02.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for BCAL Diagnostics's EPS without NRI or its related term are showing as below:
ASX:BDX'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -5.6 Med: -5.6 Max: -5.6
Current: -5.6
ASX:BDX's 3-Year EPS without NRI Growth Rate is ranked worse than 73.13% of 160
companies
in the Medical Diagnostics & Research industry
Industry Median: 10.95
vs ASX:BDX: -5.60
BCAL Diagnostics's EPS (Diluted) for the
six
months ended in Dec. 2025 was A$-0.01.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.02.
BCAL Diagnostics's EPS (Basic) for the
six
months ended in Dec. 2025 was A$-0.01.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.02.
BCAL Diagnostics (ASX:BDX) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
BCAL Diagnostics EPS without NRI Related Terms
BCAL Diagnostics EPS without NRI Historical Data
* Premium members only.
The historical data trend for BCAL Diagnostics's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:BDX vs TMO, DHR, IDXX: EPS without NRI Comparison
For the Diagnostics & Research subindustry, BCAL Diagnostics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BCAL Diagnostics PE Ratio without NRI vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, BCAL Diagnostics's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where BCAL Diagnostics's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BCAL Diagnostics (ASX:BDX) has a EPS without NRI of A$-0.02 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on BCAL Diagnostics and its competitors. According to the industry distribution chart, BCAL Diagnostics ranks #117 out of 160 companies in the Medical Diagnostics & Research industry, placing it in the top 73.1%.
Is BCAL Diagnostics' EPS without NRI too high?
BCAL Diagnostics' current EPS without NRI is A$-0.02. Based on the distribution chart, BCAL Diagnostics ranks #117 out of 160 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint.
How does BCAL Diagnostics' EPS without NRI compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, BCAL Diagnostics ranks #117 out of 160 companies for EPS without NRI. This places BCAL Diagnostics in the lower half of its industry. The industry median EPS without NRI is 10.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Diagnostics & Research company?
The median EPS without NRI among Medical Diagnostics & Research companies is 10.95, based on 160 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on BCAL Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median EPS without NRI is 10.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BCAL Diagnostics's current EPS without NRI is A$-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BCAL Diagnostics stock overvalued right now?
BCAL Diagnostics (ASX:BDX) has a current EPS without NRI of A$-0.02. The current EPS without NRI is A$-0.02. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For BCAL Diagnostics (ASX:BDX), the current EPS without NRI is A$-0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, cost-effective, accurate, and available to all women regardless of age, race, and geographic location.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BDX has been successfully added to your 